Recent events
Recent events tied to this brand in public sources.
Back to profile6 entries
2022
CSPC completes acquisition linked to a controlling stake in Mingkang Bio
CSPC Pharmaceutical Group announced it had completed the acquisition of all equity in Zhuhai Zhifan Enterprise Management Consulting Center, which primarily invests in Mingkang Bio and held approximately 51% of Mingkang Bio's registered capital.
2021
Alphamab licenses KN026 rights in mainland China to CSPC subsidiary
Alphamab Biopharmaceutical announced that its wholly owned subsidiary signed an agreement with CSPC subsidiary Shanghai JMT-Bio Technology for the development and commercialization of KN026 in mainland China.
2020
JinFang Medicine completes Series B financing
JinFang Medicine announced that it had completed a Series B financing of nearly RMB 400 million, co-led by CDH Investments and Shenzhen Capital Group's healthcare fund, with other investors participating and existing investors increasing their investment.
2019
Junshi agrees to purchase albumin-bound paclitaxel from CSPC affiliate
Junshi entered a separate sales agreement with a CSPC subsidiary to purchase up to 27,000 vials of albumin-bound paclitaxel for use until the combination-therapy clinical trial ends; Junshi paid a purchase advance.
2019
Junshi and CSPC terminate toripalimab combination cooperation
Junshi Biologics and CSPC terminated their cooperation on clinical development, registration and commercialization of toripalimab combined with albumin-bound paclitaxel for breast cancer, signing a termination agreement on December 30, 2019. Junshi will continue the clinical trial as the sole sponsor.
2019
CSPC and Junshi terminate breast cancer drug collaboration
CSPC Pharmaceutical Group and Junshi agreed to terminate their agreement for the research and commercialization of a breast cancer drug, citing potential conflict with clinical research and future commercialization of another anti-PD-1 antibody under development by CSPC.